DK155143C - Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet - Google Patents

Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Info

Publication number
DK155143C
DK155143C DK420385A DK420385A DK155143C DK 155143 C DK155143 C DK 155143C DK 420385 A DK420385 A DK 420385A DK 420385 A DK420385 A DK 420385A DK 155143 C DK155143 C DK 155143C
Authority
DK
Denmark
Prior art keywords
breast
pct
treatment
antioestrogent
boney
Prior art date
Application number
DK420385A
Other languages
Danish (da)
English (en)
Other versions
DK420385A (da
DK155143B (da
DK420385D0 (da
Inventor
Pierre Mauvais-Jarvis
Frederique Kuttenn
Original Assignee
Mauvais Jarvis Pierre
Frederique Kuttenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mauvais Jarvis Pierre, Frederique Kuttenn filed Critical Mauvais Jarvis Pierre
Publication of DK420385A publication Critical patent/DK420385A/da
Publication of DK420385D0 publication Critical patent/DK420385D0/da
Publication of DK155143B publication Critical patent/DK155143B/da
Application granted granted Critical
Publication of DK155143C publication Critical patent/DK155143C/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK420385A 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet DK155143C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8400927 1984-01-20
FR8400927A FR2558373B1 (fr) 1984-01-20 1984-01-20 Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
PCT/EP1984/000436 WO1985003228A1 (fr) 1984-01-20 1984-12-21 Medicament antioestrogene pour administration percutanee
EP8400436 1984-12-21

Publications (4)

Publication Number Publication Date
DK420385A DK420385A (da) 1985-09-17
DK420385D0 DK420385D0 (da) 1985-09-17
DK155143B DK155143B (da) 1989-02-20
DK155143C true DK155143C (da) 1989-07-03

Family

ID=9300348

Family Applications (1)

Application Number Title Priority Date Filing Date
DK420385A DK155143C (da) 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Country Status (8)

Country Link
US (1) US4919937A (de)
EP (2) EP0151326B1 (de)
JP (1) JPH0667826B2 (de)
AT (1) ATE73334T1 (de)
DE (1) DE3485581D1 (de)
DK (1) DK155143C (de)
FR (1) FR2558373B1 (de)
WO (1) WO1985003228A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
ZA901847B (en) * 1989-03-10 1991-10-30 Endorecherche Inc Combination therapy for the treatment of estrogen sensitive diseases
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
ES2156361T5 (es) 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
RU2123838C1 (ru) * 1996-07-31 1998-12-27 Акционерное общество открытого типа "Нижфарм" Состав для лечения гирсутизма
US20020086856A1 (en) 1998-03-18 2002-07-04 Alfred Schmidt Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
EP0943333A1 (de) * 1998-03-18 1999-09-22 S.W. Patentverwertungs GmbH Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
FI982733L (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US8119138B2 (en) * 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
US7863011B2 (en) * 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
MXPA02011092A (es) 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
WO2003041654A2 (en) * 2001-11-14 2003-05-22 Sirbasku David A Anti-estrogen and immune modulator combinations for treating breast cancer
JP2005513080A (ja) 2001-12-20 2005-05-12 フェムファーマ, インコーポレイテッド 薬物の膣送達
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル 4−ヒドロキシタモキシフェンによる乳房密度低下
WO2004054557A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP2006515026A (ja) 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー, インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) * 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
PL1694319T3 (pl) * 2003-12-15 2009-01-30 Besins Healthcare Lu Sarl Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1550440A1 (de) * 2003-12-15 2005-07-06 Laboratoires Besins International Verwendung von 4-hydroxytamoxifen zur Herstellung eines Arzneimittels zur Behandlung von Gynäkomastie
CN1946387B (zh) * 2004-03-22 2011-08-31 法国法杏大药厂 4-羟基三苯氧胺在制备治疗和预防良性乳房疾病的药物中的应用
EP1579857A1 (de) * 2004-03-22 2005-09-28 Laboratoires Besins International Stabile Zusammensetzungen enthaltend 4-hydroxy Tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (de) * 2004-03-22 2005-09-28 Laboratoires Besins International 4-Hydroxytamoxifen zur Behandlung von benignen Brusterkrankungen
EP1647271A1 (de) * 2004-10-14 2006-04-19 Laboratoires Besins International Gelzubereitung enthaltend 4-Hydroxy tamoxifen.
EP1799201B1 (de) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxytamoxifengel-formulierungen
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
KR100850910B1 (ko) * 2006-12-22 2008-08-07 삼성전자주식회사 블루투스 디바이스를 연결하기 위한 장치 및 방법
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FR2515041A1 (fr) 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires

Also Published As

Publication number Publication date
DK420385A (da) 1985-09-17
EP0169214A1 (de) 1986-01-29
EP0151326B1 (de) 1989-07-12
EP0169214B1 (de) 1992-03-11
FR2558373A1 (fr) 1985-07-26
ATE73334T1 (de) 1992-03-15
FR2558373B1 (fr) 1987-07-03
JPH0667826B2 (ja) 1994-08-31
US4919937A (en) 1990-04-24
WO1985003228A1 (fr) 1985-08-01
DK155143B (da) 1989-02-20
EP0151326A1 (de) 1985-08-14
DE3485581D1 (de) 1992-04-16
DK420385D0 (da) 1985-09-17
JPS61500914A (ja) 1986-05-08

Similar Documents

Publication Publication Date Title
DK155143C (da) Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
DE69531457D1 (en) Sulfonamide
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DE69229050D1 (de) Verwendung von Papillomavirusprotein L2 zur therapeutischen Behandlung von durch Papillomavirus hervorgerufenen Tumoren oder oder anderen krankhaften Veränderungen
ATE86858T1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
EP0009688A3 (en) Medicated animal food based on liver powder, process for its preparation and its use in combating animal diseases
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
JPS57122085A (en) Circulatory disease extirpenter and use
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
BR0113461A (pt) Compostos ou sais farmaceuticamente aceitáveis, composições farmacêuticas, método de tratamento de doença ou condição mediada por erab, hadh2 ou (beta)-amilóide em mamìferos, métodos de inibição ou modulação da atividade enzimática de erab ou hadh2 e método de tratamento de mal de alzheimer ou demência em mamìferos
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
BR8008818A (pt) Peptidos farmacologicamente ativos e medicamentos contendo os mesmos
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
DK12388A (da) Sialosylcholesterol, fremgangsmaade til fremstilling af og neuropatimiddel omfattende samme
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ES8106498A1 (es) Un procedimiento para la preparacion de derivados del pirrol
PT85454A (de) Verwendung von 15-deoxyspergualin als arzneimittel
PT98764A (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos